Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23868
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCioccari, Luca-
dc.contributor.authorLuethi, Nora-
dc.contributor.authorBailey, Michael-
dc.contributor.authorShehabi, Yahya-
dc.contributor.authorHowe, Belinda-
dc.contributor.authorMessmer, Anna S-
dc.contributor.authorProimos, Helena K-
dc.contributor.authorPeck, Leah-
dc.contributor.authorYoung, Helen-
dc.contributor.authorEastwood, Glenn M-
dc.contributor.authorMerz, Tobias M-
dc.contributor.authorTakala, Jukka-
dc.contributor.authorJakob, Stephan M-
dc.contributor.authorBellomo, Rinaldo-
dc.date2020-07-16-
dc.date.accessioned2020-07-27T05:09:34Z-
dc.date.available2020-07-27T05:09:34Z-
dc.date.issued2020-07-16-
dc.identifier.citationCritical Care 2020; 24(1): 441-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/23868-
dc.description.abstractSeptic shock is associated with decreased vasopressor responsiveness. Experimental data suggest that central alpha2-agonists like dexmedetomidine (DEX) increase vasopressor responsiveness and reduce catecholamine requirements in septic shock. However, DEX may also cause hypotension and bradycardia. Thus, it remains unclear whether DEX is hemodynamically safe or helpful in this setting. In this post hoc subgroup analysis of the Sedation Practice in Intensive Care Evaluation (SPICE III) trial, an international randomized trial comparing early sedation with dexmedetomidine to usual care in critically patients receiving mechanical ventilation, we studied patients with septic shock admitted to two tertiary ICUs in Australia and Switzerland. The primary outcome was vasopressor requirements in the first 48 h after randomization, expressed as noradrenaline equivalent dose (NEq [μg/kg/min] = noradrenaline + adrenaline + vasopressin/0.4). Between November 2013 and February 2018, 417 patients were recruited into the SPICE III trial at both sites. Eighty-three patients with septic shock were included in this subgroup analysis. Of these, 44 (53%) received DEX and 39 (47%) usual care. Vasopressor requirements in the first 48 h were similar between the two groups. Median NEq dose was 0.03 [0.01, 0.07] μg/kg/min in the DEX group and 0.04 [0.01, 0.16] μg/kg/min in the usual care group (p = 0.17). However, patients in the DEX group had a lower NEq/MAP ratio, indicating lower vasopressor requirements to maintain the target MAP. Moreover, on adjusted multivariable analysis, higher dexmedetomidine dose was associated with a lower NEq/MAP ratio. In critically ill patients with septic shock, patients in the DEX group received similar vasopressor doses in the first 48 h compared to the usual care group. On multivariable adjusted analysis, dexmedetomidine appeared to be associated with lower vasopressor requirements to maintain the target MAP. The SPICE III trial was registered at ClinicalTrials.gov ( NCT01728558 ).-
dc.language.isoeng-
dc.subjectDexmedetomidine-
dc.subjectHemodynamics-
dc.subjectNoradrenaline-
dc.subjectSedation-
dc.subjectSepsis-
dc.subjectSeptic shock-
dc.titleThe effect of dexmedetomidine on vasopressor requirements in patients with septic shock: a subgroup analysis of the Sedation Practice in Intensive Care Evaluation [SPICE III] Trial.-
dc.typeJournal Articleen
dc.identifier.journaltitleCritical Care-
dc.identifier.affiliationCardiovascular Intensive Care Unit (CVICU), Auckland City Hospital, Auckland, New Zealanden
dc.identifier.affiliationInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerlanden
dc.identifier.affiliationDepartment of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerlanden
dc.identifier.affiliationIntensive Careen
dc.identifier.affiliationClinical School of Medicine, University New South Wales, Sydney, Australiaen
dc.identifier.affiliationCritical Care and Perioperative Services, School of Clinical Sciences, Monash University, Monash Health, Melbourne, Australiaen
dc.identifier.affiliationAustralian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland-
dc.identifier.doi10.1186/s13054-020-03115-x-
dc.type.contentTexten
dc.identifier.orcid0000-0003-4993-427X-
dc.identifier.pubmedid32678054-
dc.type.austinJournal Article-
dc.type.austinResearch Support, Non-U.S. Gov't-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on May 17, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.